Divergent activation of the RXFP1 relaxin receptor by protein and small-molecule agonists

The relaxin receptor RXFP1 is a therapeutic target owing to its potential benefits in the treatment of fibrosis and heart failure. Protein and small-molecule agonists are currently in midstage clinical trials for various forms of heart disease. In this work, we present three cryo–electron microscopy structures of RXFP1: ligand-free, bound to the native agonist relaxin-2, and bound to the small-molecule drug candidate AZD5462. These structures reveal that relaxin-2 engages the receptor’s ectodomain, whereas AZD5462 binds to the transmembrane domain. Together with hydrogen-deuterium exchange mass spectrometry, we show that relaxin-2 induces reorganization of the linker domain into a helical secondary structure. By contrast, AZD5462 stabilizes an active conformation through a distinct set of conformational rearrangements. Altogether, our findings define divergent activation mechanisms for protein and small-molecule agonists of RXFP1.

Authors

Institutions

Publication Details

Journal
Science
Published
2026-11-19
DOI
https://doi.org/10.1126/science.aei0135
Citations
1
Primary Topic
Receptor Mechanisms and Signaling
Type
article
Field-Weighted Citation Impact
1.12

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Divergent activation of the RXFP1 relaxin receptor by protein and small-molecule agonists

Mark W. Grinstaff, Xunan Wang, Pengxiang Shen, James Osei‐Owusu et al.
1 citations
Science
Receptor Mechanisms and Signaling
1.12
article

Divergent activation of the RXFP1 relaxin receptor by protein and small-molecule agonists

Mark W. Grinstaff, Xunan Wang, Pengxiang Shen, James Osei‐Owusu, Xiaojing Cong, Sarah C. Erlandson, Jeffrey S. Smith, Chérine Bechara, Amanda K. Williamson, Andrew C. Kruse, Tristan Girbau, Daniel Kahne
article en
1 citations

Abstract

The relaxin receptor RXFP1 is a therapeutic target owing to its potential benefits in the treatment of fibrosis and heart failure. Protein and small-molecule agonists are currently in midstage clinical trials for various forms of heart disease. In this work, we present three cryo–electron microscopy structures of RXFP1: ligand-free, bound to the native agonist relaxin-2, and bound to the small-molecule drug candidate AZD5462. These structures reveal that relaxin-2 engages the receptor’s ectodomain, whereas AZD5462 binds to the transmembrane domain. Together with hydrogen-deuterium exchange mass spectrometry, we show that relaxin-2 induces reorganization of the linker domain into a helical secondary structure. By contrast, AZD5462 stabilizes an active conformation through a distinct set of conformational rearrangements. Altogether, our findings define divergent activation mechanisms for protein and small-molecule agonists of RXFP1.

ScienceVol. 394(6826)
Boston University (US), Brigham and Women's Hospital (US), Centre National de la Recherche Scientifique (FR), Harvard University (US), Inserm (FR), Université de Montpellier (FR), Institut de Génomique Fonctionnelle (FR), Vertex Pharmaceuticals (United States) (US)
Howard Hughes Medical Institute, Agence Nationale de la Recherche, Région Occitanie Pyrénées-Méditerranée, National Institutes of Health, European Regional Development Fund, National Institute of Arthritis and Musculoskeletal and Skin Diseases
Good health and well-being
Openalex Percentile: Top 31%
Receptor Mechanisms and Signaling
1.12
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon